<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Causes of central adrenal insufficiency in children</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Causes of central adrenal insufficiency in children</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Causes of central adrenal insufficiency in children</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mimi S Kim, MD, MSc</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mitchell E Geffner, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 22, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Adrenal insufficiency is a potentially life-threatening condition defined by the inability of the adrenal cortex to produce sufficient cortisol [<a href="#rid1">1</a>]. Primary adrenal insufficiency is caused by disease intrinsic to the adrenal cortex that interferes with cortisol production and can also involve mineralocorticoid deficiency. Central adrenal insufficiency is caused by impaired production of corticotrophin-releasing hormone (CRH) and/or adrenocorticotropic hormone (ACTH), usually associated with abrupt withdrawal of glucocorticoid pharmacotherapy or central nervous system disease.</p><p>The causes of central adrenal insufficiency will be discussed in this topic review. Other aspects of adrenal insufficiency are discussed in separate topic reviews:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5828.html" rel="external">"Clinical manifestations and diagnosis of adrenal insufficiency in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5813.html" rel="external">"Causes of primary adrenal insufficiency in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5825.html" rel="external">"Treatment of adrenal insufficiency in children"</a>.)</p><p></p><p class="headingAnchor" id="H2001455063"><span class="h1">CLASSIFICATION</span><span class="headingEndMark"> — </span>Central adrenal insufficiency is characterized by impaired production of adrenocorticotropic hormone (ACTH). It can be caused by either pituitary disease that impairs production of ACTH (secondary adrenal insufficiency) or by interference with corticotropin-releasing hormone release from the hypothalamus (tertiary adrenal insufficiency).</p><p>For clinical purposes, it is useful to classify central adrenal insufficiency by the expected time course  (<a class="graphic graphic_table graphicRef56675" href="/z/d/graphic/56675.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transient adrenal insufficiency</strong> – In many cases of tertiary adrenal insufficiency, the hypothalamus and pituitary are transiently suppressed by negative feedback from exogenous or endogenous hormones. This is the case with exogenous glucocorticoid treatment, which is the most common cause of central adrenal insufficiency. (See <a class="local">'Transient central adrenal insufficiency (hypothalamic suppression)'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Permanent adrenal insufficiency</strong> – Other disorders cause permanent adrenal insufficiency due to irreversible dysfunction or injury to the hypothalamus (certain cases of tertiary adrenal insufficiency) and/or pituitary (secondary adrenal insufficiency). (See <a class="local">'Permanent central adrenal insufficiency'</a> below.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">OVERVIEW OF CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Central adrenal insufficiency is characterized by:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glucocorticoid deficiency</strong> – Signs and symptoms include weakness, fatigue, myalgia, arthralgia, and hypoglycemia, which may be severe. These clinical findings are similar to those seen in primary adrenal insufficiency [<a href="#rid2">2</a>]. In newborns, the most common presenting signs are hypoglycemia (sometimes with growth failure or seizures) and prolonged cholestatic jaundice. Hyperpigmentation is absent (in contrast with patients with primary adrenal insufficiency) because adrenocorticotropic hormone (ACTH) is not elevated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Central nervous system abnormalities </strong>– In addition, some patients may have signs or symptoms related to an underlying central nervous system disease and/or other pituitary hormone deficiencies.</p><p></p><p>(See  <a class="medical medical_review" href="/z/d/html/5828.html" rel="external">"Clinical manifestations and diagnosis of adrenal insufficiency in children", section on 'Central adrenal insufficiency'</a>.)</p><p class="headingAnchor" id="H1049110413"><span class="h1">TRANSIENT CENTRAL ADRENAL INSUFFICIENCY (HYPOTHALAMIC SUPPRESSION)</span><span class="headingEndMark"> — </span>Suppression of the hypothalamic-pituitary-adrenal (HPA) axis causing isolated adrenocorticotropic hormone (ACTH) deficiency is the most common cause of central adrenal insufficiency  (<a class="graphic graphic_table graphicRef56675" href="/z/d/graphic/56675.html" rel="external">table 1</a>). Most cases are the result of chronic high-dose exogenous glucocorticoid therapy or other forms of excessive glucocorticoid exposure. The adrenal insufficiency becomes clinically apparent when the glucocorticoid is abruptly withdrawn.</p><p class="headingAnchor" id="H3417952629"><span class="h2">Glucocorticoids</span></p><p class="headingAnchor" id="H918445527"><span class="h3">Chronic high-dose glucocorticoid therapy</span><span class="headingEndMark"> — </span>Exogenous glucocorticoid (corticosteroid) therapy suppresses the normal function and feedback mechanism of the HPA axis. When the exogenous glucocorticoids are stopped, the suppressed HPA axis initially fails to produce sufficient ACTH. This is especially evident during periods of stress (eg, surgery, major trauma, or infection). As an example, adrenal suppression has been observed in patients with childhood acute lymphoblastic leukemia after cessation of glucocorticoid therapy [<a href="#rid3">3</a>].</p><p>The likelihood of HPA suppression is not entirely predictable, but the risk is associated with dose, duration, and route of glucocorticoid therapy:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Systemic glucocorticoids</strong> – HPA suppression is unlikely if the glucocorticoid dose administered is less than the amount needed for physiologic maintenance therapy or if the dose was greater than physiologic maintenance therapy but treatment duration was less than four weeks. In this setting, there is no need to wean the glucocorticoid dose and no need for exogenous glucocorticoid therapy for stressful events.</p><p></p><p class="bulletIndent1">By contrast, HPA suppression is likely if the glucocorticoid dose was greater than physiologic maintenance therapy and the duration of replacement therapy was greater than four weeks. Recovery of adrenal function occurs within six weeks in approximately one-half of the patients and within six months for almost all patients [<a href="#rid4">4</a>]. During this time period, exogenous glucocorticoid therapy (ie, stress dosing) with <a class="drug drug_pediatric" data-topicid="13361" href="/z/d/drug information/13361.html" rel="external">hydrocortisone</a> may be needed for physiologic stress (eg, systemic illness, trauma, or surgery). (See  <a class="medical medical_review" href="/z/d/html/7983.html" rel="external">"Glucocorticoid withdrawal", section on 'Hypothalamic-pituitary-adrenal axis suppression'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topical or inhaled glucocorticoids</strong> – Although suppression of the HPA axis is usually associated with oral or parenteral glucocorticoid therapy, suppression can occasionally occur after the cessation of topical glucocorticoid therapy contained in nasal sprays [<a href="#rid5">5</a>], eye drops [<a href="#rid6">6</a>], inhaled products [<a href="#rid7">7-9</a>], dermal creams or lotions [<a href="#rid10">10</a>] (including <a class="drug drug_pediatric" data-topicid="12609" href="/z/d/drug information/12609.html" rel="external">clobetasol</a> prescribed for diaper rash treatment [<a href="#rid11">11</a>]), or oral viscous <a class="drug drug_pediatric" data-topicid="13319" href="/z/d/drug information/13319.html" rel="external">fluticasone</a> or <a class="drug drug_pediatric" data-topicid="13096" href="/z/d/drug information/13096.html" rel="external">budesonide</a> used to treat eosinophilic esophagitis [<a href="#rid12">12</a>]. Some factors that increase risk for adrenal suppression include high potency of the topical glucocorticoid, ointment (rather than cream) formulation, duration and amount used, younger patient age (which is associated with increased dermal absorption), and skin thickness [<a href="#rid11">11</a>]. (See  <a class="medical medical_review" href="/z/d/html/5565.html" rel="external">"Topical corticosteroids: Use and adverse effects", section on 'Systemic'</a> and  <a class="medical medical_review" href="/z/d/html/540.html" rel="external">"Major side effects of inhaled glucocorticoids", section on 'Adrenal suppression'</a>.)</p><p></p><p class="headingAnchor" id="H102546290"><span class="h3">Endogenous Cushing syndrome</span><span class="headingEndMark"> — </span>Cushing syndrome can be caused by an ACTH-secreting tumor (Cushing disease) or a cortisol-secreting adrenal tumor. In either case, the chronically high serum cortisol concentrations before surgery suppress the HPA axis. After removal of the tumor, patients have temporary central adrenal insufficiency that requires glucocorticoid replacement, especially during episodes of physiologic stress (eg, surgery, trauma, or infection). (See  <a class="medical medical_review" href="/z/d/html/173.html" rel="external">"Causes of secondary and tertiary adrenal insufficiency in adults", section on 'After the cure of Cushing syndrome'</a>.)</p><p class="headingAnchor" id="H2855295280"><span class="h2">Other drugs</span><span class="headingEndMark"> — </span>Other drugs that can cause transient central adrenal insufficiency by affecting target tissues, including the hypothalamus and/or pituitary, include (see  <a class="medical medical_review" href="/z/d/html/173.html" rel="external">"Causes of secondary and tertiary adrenal insufficiency in adults", section on 'Drugs'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Megestrol acetate</strong> – <a class="drug drug_pediatric" data-topicid="12578" href="/z/d/drug information/12578.html" rel="external">Megestrol acetate</a> (Megace) is a high-dose progestin with glucocorticoid activity; adrenal insufficiency may occur during therapy or upon withdrawal.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Opioids</strong> – Long-term opioid treatment can impair the HPA axis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mifepristone</strong> – <a class="drug drug_general" data-topicid="10263" href="/z/d/drug information/10263.html" rel="external">Mifepristone</a>, an anti-progestational drug, can cause central adrenal insufficiency because it is also a glucocorticoid receptor antagonist. It is primarily used to terminate pregnancy but occasionally is used to treat hypercortisolism. (See  <a class="medical medical_review" href="/z/d/html/119.html" rel="external">"Medical therapy of hypercortisolism (Cushing's syndrome)", section on 'Glucocorticoid-receptor antagonists'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antipsychotics</strong> (chlorpromazine), <strong>antidepressants</strong> (imipramine) – These drugs cause glucocorticoid resistance by interfering with glucocorticoid-induced gene transcription in central components of the HPA axis [<a href="#rid13">13,14</a>].</p><p></p><p class="headingAnchor" id="H1510403461"><span class="h2">Anorexia nervosa</span><span class="headingEndMark"> — </span>Patients with anorexia nervosa often have some degree of hypothalamic dysfunction, including secondary amenorrhea (decreased gonadotrophin secretion) and hypothyroidism (decreased secretion of thyroid-stimulating hormone). Central adrenal insufficiency is rare: Only a few case reports describe patients who have a blunted ACTH response to stress that may lead to episodes of adrenal insufficiency [<a href="#rid15">15</a>]. Instead, patients with anorexia nervosa tend to have elevated ACTH and serum cortisol concentrations, potentially as a mechanism to maintain euglycemia, with corticotropin-releasing hormone hypersecretion [<a href="#rid16">16</a>]. (See  <a class="medical medical_review" href="/z/d/html/86685.html" rel="external">"Anorexia nervosa: Endocrine complications and their management", section on 'Hypothalamic-pituitary abnormalities'</a>.)</p><p class="headingAnchor" id="H499864122"><span class="h2">Critical illness-related corticosteroid insufficiency</span><span class="headingEndMark"> — </span>Critical illness-related corticosteroid insufficiency is characterized by altered cortisol metabolism and tissue resistance to corticosteroids, as well as dysregulation of the HPA axis involving multiple mechanisms [<a href="#rid17">17</a>]. (See  <a class="medical medical_review" href="/z/d/html/5813.html" rel="external">"Causes of primary adrenal insufficiency in children", section on 'Critical illness-related corticosteroid insufficiency'</a>.)</p><p class="headingAnchor" id="H1021129170"><span class="h1">PERMANENT CENTRAL ADRENAL INSUFFICIENCY</span><span class="headingEndMark"> — </span>Permanent central adrenal insufficiency can be caused by either pituitary dysfunction (secondary adrenal insufficiency) or hypothalamic dysfunction (tertiary adrenal insufficiency) and can be congenital or acquired  (<a class="graphic graphic_table graphicRef56675" href="/z/d/graphic/56675.html" rel="external">table 1</a>):</p><p class="headingAnchor" id="H724265384"><span class="h2">Congenital causes</span></p><p class="headingAnchor" id="H2562741447"><span class="h3">Brain malformations</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Optic nerve hypoplasia (historically known as septo-optic dysplasia)</strong> – This condition (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F182230&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfjmmX14QGylCDpT81AUMQzRxTBqJy%2FVfWe4hwoCzpk&amp;TOPIC_ID=5815" target="_blank">MIM #182230</a>) is characterized by optic nerve hypoplasia; one-half of the cases have associated structural pituitary abnormalities (hypoplasia and/or ectopic posterior pituitary) and/or absence of the septum pellucidum [<a href="#rid18">18</a>]. Affected patients often have multiple pituitary hormone abnormalities, especially growth hormone deficiency and hyperprolactinemia; approximately one-third of patients have central adrenal insufficiency. The disorder is rarely caused by variants in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F601802&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyqx2W04NeH5F4ju5deEfEa0&amp;TOPIC_ID=5815" target="_blank"><i>HESX1</i></a> and other genes involved in pituitary development [<a href="#rid19">19,20</a>], but, in most cases, the cause is unknown. Optic nerve hypoplasia can also be isolated, without related pituitary or brain abnormalities. (See  <a class="medical medical_review" href="/z/d/html/6267.html" rel="external">"Congenital and acquired abnormalities of the optic nerve", section on 'Hypoplasia'</a> and <a class="local">'Genetic causes of pituitary hormone deficiencies'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other</strong> – Other midline brain defects including holoprosencephaly may be associated with hypothalamic or pituitary dysfunction, often with associated craniofacial clefts. (See  <a class="medical medical_review" href="/z/d/html/2920.html" rel="external">"Overview of craniofacial clefts and holoprosencephaly"</a>.)</p><p></p><p class="headingAnchor" id="H413750188"><span class="h3">Syndromes with hypothalamic dysfunction</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prader-Willi syndrome</strong> – Prader-Willi syndrome (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F176270&amp;token=tEpDslnpc0F0kICl%2Fz7sFRpMsbswgmBJuV5MFhYv5gArdKg0PSSwXhzjP5FWa%2FlL&amp;TOPIC_ID=5815" target="_blank">MIM #176270</a>) involves multiple endocrine abnormalities, and a key feature of the syndrome is hypothalamic dysfunction. Endocrine and metabolic complications include growth hormone deficiency and short stature, hyperphagia and central obesity, hypogonadism, hypothyroidism, and osteoporosis. A minority of patients have associated adrenal insufficiency; however, there is a varying prevalence depending on the stimulation test used to evaluate central adrenal insufficiency in this condition [<a href="#rid21">21-23</a>]. In one study, 60 percent of patients with Prader-Willi syndrome had an abnormal response to a test of adrenocorticotropic hormone (ACTH) secretory ability (<a class="drug drug_pediatric" data-topicid="12607" href="/z/d/drug information/12607.html" rel="external">metyrapone</a> test) [<a href="#rid24">24</a>], suggesting that they might be at risk for acute adrenal insufficiency under stress conditions. (See  <a class="medical medical_review" href="/z/d/html/5864.html" rel="external">"Prader-Willi syndrome: Management", section on 'Hypothalamic and pituitary dysfunction'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>ROHHAD syndrome</strong> – This rare syndrome is characterized by <strong>r</strong>apid-onset <strong>o</strong>besity, <strong>h</strong>ypothalamic dysfunction, <strong>h</strong>ypoventilation, and <strong>a</strong>utonomic <strong>d</strong>ysregulation (ROHHAD) and is sometimes also associated with neuroectodermal tumors. Manifestations of hypothalamic dysfunction include Cushing-like features, growth hormone deficiency, precocious puberty, hyperprolactinemia, central hypothyroidism, and hypernatremia (with or without arginine vasopressin deficiency [previously known as central diabetes insipidus]). Adrenal insufficiency has been reported in approximately one-third of cases [<a href="#rid25">25</a>]. (See  <a class="medical medical_review" href="/z/d/html/97858.html" rel="external">"Congenital central hypoventilation syndrome and other causes of sleep-related hypoventilation in children", section on 'Rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation (ROHHAD)'</a>.)</p><p></p><p class="headingAnchor" id="H2622940030"><span class="h3">Genetic causes of pituitary hormone deficiencies</span><span class="headingEndMark"> — </span>Genetic defects that interfere with development of the pituitary gland are an uncommon cause of secondary adrenal insufficiency. Defects in transcription factors involved in pituitary development may cause combined pituitary hormone deficiencies (CPHD), in which one or more anterior pituitary hormones are deficient  (<a class="graphic graphic_table graphicRef80512" href="/z/d/graphic/80512.html" rel="external">table 2</a>) [<a href="#rid26">26</a>]. There is heterogeneity involved with CPHD, although other mutations (eg, <em>POU1F1</em>) do not always result in central adrenal insufficiency (ACTH deficiency; see genetic heterogeneity of CPHD at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F613038&amp;token=87jLzclRwWxNoI%2BQq5Gg79EohNg39%2FjiwBo6FcqYyO8mrA71Cqa%2BrZ8zaxHmx%2B10&amp;TOPIC_ID=5815" target="_blank">MIM #613038</a>). (See  <a class="medical medical_review" href="/z/d/html/6636.html" rel="external">"Causes of hypopituitarism", section on 'Genetic diseases'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonsyndromic</strong> – A nonsyndromic form of CPHD has been associated with mutations in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F601538&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyr2U1EafXgCR1ddbBZNpfza&amp;TOPIC_ID=5815" target="_blank"><i>PROP1</i></a> gene (CHPD type 2, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F613038&amp;token=87jLzclRwWxNoI%2BQq5Gg79EohNg39%2FjiwBo6FcqYyO8mrA71Cqa%2BrZ8zaxHmx%2B10&amp;TOPIC_ID=5815" target="_blank">MIM #262600</a>). <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F601538&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyr2U1EafXgCR1ddbBZNpfza&amp;TOPIC_ID=5815" target="_blank">PROP1</a> is required for the differentiation of anterior pituitary cells to somatotroph, lactotroph, thyrotroph, and gonadotroph cells. Individuals with <em>PROP1</em> defects have variable clinical phenotypes regarding hormonal defects, timing and order of onset, and severity. The presence of ACTH deficiency is variable. In those with ACTH deficiency, the onset may vary from childhood to late adulthood [<a href="#rid20">20,27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Syndromic</strong> – Syndromic forms of CPHD have been associated with other transcription factors involved in pituitary development. Genes that are sometimes associated with ACTH deficiency include <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F313430&amp;token=87jLzclRwWxNoI%2BQq5Gg7yBbFbx6UdCHxk8eBgov2B%2FzaGMSjdHtFOqCNPX3HxZV&amp;TOPIC_ID=5815" target="_blank"><i>SOX3</i></a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F607108&amp;token=87jLzclRwWxNoI%2BQq5Gg79SuJM%2B4PyjKVen0hh%2B0Thy8n5s5ls02F3e85aUSXc78&amp;TOPIC_ID=5815" target="_blank"><i>PAX6</i></a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F600577&amp;token=87jLzclRwWxNoI%2BQq5Gg7zegynyYM9eYVNUnIpOULaIWOHcftzMjNDuxyIKPqrDg&amp;TOPIC_ID=5815" target="_blank"><i>LHX3</i></a>, and <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F602146&amp;token=87jLzclRwWxNoI%2BQq5Gg70f6mI0ksCO7lh0Lnk2ZF7gTZs3OCLiMrfwqnVU5so%2FN&amp;TOPIC_ID=5815" target="_blank"><i>LHX4</i></a>.</p><p></p><p class="bulletIndent1"><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F164012&amp;token=tEpDslnpc0F0kICl%2Fz7sFQZkXc5y3Ni5EtCdXl4313U00nnJy%2BZ7z2w67lM%2F7W%2BW&amp;TOPIC_ID=5815" target="_blank"><i>NF</i><i>KB2</i></a> mutations are associated with common variable immunodeficiency-10 and, in some cases, ACTH deficiency with or without other pituitary hormone deficiencies (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F615577&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz5LmHlIWQc5vBkqgQaxX3vj&amp;TOPIC_ID=5815" target="_blank">MIM #615577</a>) [<a href="#rid28">28,29</a>].</p><p></p><p class="bulletIndent1"><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F601802&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyqx2W04NeH5F4ju5deEfEa0&amp;TOPIC_ID=5815" target="_blank"><i>HESX1</i></a> mutations are associated with optic nerve hypoplasia as well as ACTH deficiency [<a href="#rid20">20</a>]. (See <a class="local">'Brain malformations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Syndromic with isolated ACTH deficiency</strong> – Isolated ACTH deficiency is a rare cause of secondary adrenal insufficiency. It can present with hypoglycemia due to low cortisol levels. It is caused by one of several mutations in the biosynthetic pathway of ACTH:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F176830&amp;token=tEpDslnpc0F0kICl%2Fz7sFRpMsbswgmBJuV5MFhYv5gCqkfixf7XygE2kvY5msQGr&amp;TOPIC_ID=5815" target="_blank"><i>POMC</i></a> mutations – Proopiomelanocortin (POMC) is a precursor to ACTH. Patients with <em>POMC</em> mutations present with early-onset obesity, red hair, and secondary adrenal insufficiency (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F609734&amp;token=tEpDslnpc0F0kICl%2Fz7sFRE1gkgqgJF7T6niZxjpYaGhgMNRx%2FAuPYgvUj1BO%2FL5&amp;TOPIC_ID=5815" target="_blank">MIM #609734</a>). (See  <a class="medical medical_review" href="/z/d/html/5378.html" rel="external">"Obesity: Genetic contribution and pathophysiology", section on 'Proopiomelanocortin'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F604614&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyq6FIljXXAxjopY0GpyUnQw&amp;TOPIC_ID=5815" target="_blank"><i>TBX19</i></a> (<em>TPIT</em>) mutations – TBX19 is a transcription factor required for corticotroph differentiation and POMC production. <em>TBX19</em> mutations are rare; affected patients present with hypoglycemia and/or cholestasis as neonates (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F201400&amp;token=tEpDslnpc0F0kICl%2Fz7sFRq9f0MGN2Oxgakbp76u2bGsl5YebBgqZBMNWXT3sQO%2B&amp;TOPIC_ID=5815" target="_blank">MIM #201400</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F162150&amp;token=tEpDslnpc0F0kICl%2Fz7sFQZkXc5y3Ni5EtCdXl4313Xu2LY4k7qdBgJac0xuv541&amp;TOPIC_ID=5815" target="_blank"><i>PCSK1</i></a> mutations – Case reports describe mutations in the <em>PCSK1</em> gene, which are associated with defective post-translational processing of ACTH, insulin precursors, and some other prohormones [<a href="#rid30">30-33</a>]. Clinical manifestations include obesity, hypogonadism, hypoadrenalism, postprandial hypoglycemia, and, sometimes, chronic diarrhea (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F600955&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyr%2FH130otPc6SALuL21H52T&amp;TOPIC_ID=5815" target="_blank">MIM #600955</a>, also known as DAVID syndrome) [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent1">A more detailed discussion of these genetic disorders is found in a separate topic review. (See  <a class="medical medical_review" href="/z/d/html/173.html" rel="external">"Causes of secondary and tertiary adrenal insufficiency in adults"</a>.)</p><p></p><p class="headingAnchor" id="H272138588"><span class="h2">Acquired causes</span><span class="headingEndMark"> — </span>Any process that disrupts hypothalamic or pituitary function can cause central adrenal insufficiency. Multiple pituitary hormones may be affected (growth hormone, luteinizing hormone, follicle-stimulating hormone, thyroid-stimulating hormone, ACTH, and/or antidiuretic hormone). The most common deficits are growth hormone, luteinizing hormone, and follicle-stimulating hormone, causing growth abnormalities and delayed puberty, respectively.</p><p class="headingAnchor" id="H3258004576"><span class="h3">Brain lesion or injury</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Brain tumor or cranial radiation</strong> – Tumors that arise in and around the sella turcica (eg, craniopharyngioma, the most common pediatric brain tumor) may result in hypopituitarism. Patients who have had surgery or cranial radiation for brain tumors in the region of the pituitary gland or hypothalamus also are at risk for developing hypopituitarism, if the tumor itself has not already resulted in hypopituitarism. Cranial radiation is sometimes used prophylactically for patients with certain cancers outside of the central nervous system, including leukemias.</p><p></p><p class="bulletIndent1">The risk from cranial radiation is dependent upon the field and dose of radiation, with an estimated prevalence of 3.2 percent for ACTH deficiency in survivors of childhood cancer who were treated with hypothalamic-pituitary radiotherapy, in particular those exposed to ≥30 Gy [<a href="#rid35">35,36</a>].</p><p></p><p class="bulletIndent1">Survivors should have annual lifelong monitoring for development of ACTH deficiency and other endocrinopathies, which can develop at any time. ACTH deficiency is less common than other pituitary hormone deficiencies; the risk depends on the dose of hypothalamic-pituitary radiation and time from radiation therapy [<a href="#rid37">37</a>]. (See  <a class="medical medical_review" href="/z/d/html/5210.html" rel="external">"Craniopharyngioma"</a> and  <a class="medical medical_review" href="/z/d/html/93313.html" rel="external">"Endocrinopathies in cancer survivors and others exposed to cytotoxic therapies during childhood", section on 'Hypothalamic-pituitary dysfunction'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Brain trauma or surgery</strong> – Traumatic brain injury may result in hemorrhage in the pituitary gland or hypothalamus, resulting in hypopituitarism. In the premature infant, nontraumatic intracranial hemorrhage also can cause hypopituitarism. (See  <a class="medical medical_review" href="/z/d/html/6636.html" rel="external">"Causes of hypopituitarism", section on 'Traumatic brain injury'</a>.)</p><p></p><p class="headingAnchor" id="H777373316"><span class="h3">Infiltrative diseases</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Iron overload</strong> – Patients who require multiple transfusions and have iron overload are at risk for deficiencies of pituitary hormones, including gonadotropins and ACTH. This includes patients with thalassemia major, particularly males [<a href="#rid38">38-40</a>], or hereditary hemochromatosis, with iron deposition noted in the adrenal glands and pituitary gland on magnetic resonance imaging [<a href="#rid41">41</a>]. It is not known if the ACTH deficiency is reversible with appropriate chelation therapy. (See  <a class="medical medical_review" href="/z/d/html/7116.html" rel="external">"Diagnosis of thalassemia (adults and children)", section on 'Endocrine and metabolic abnormalities'</a> and  <a class="medical medical_review" href="/z/d/html/7167.html" rel="external">"Clinical manifestations and diagnosis of hereditary hemochromatosis", section on 'Hypopituitarism, hypogonadism, and hypothyroidism'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infiltrative diseases</strong> – Other conditions that destroy the normal hypothalamic tissues by infiltration include sarcoidosis or Langerhans cell histiocytosis. (See  <a class="medical medical_review" href="/z/d/html/7167.html" rel="external">"Clinical manifestations and diagnosis of hereditary hemochromatosis"</a> and  <a class="medical medical_review" href="/z/d/html/4834.html" rel="external">"Neurologic sarcoidosis"</a> and  <a class="medical medical_review" href="/z/d/html/8385.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis"</a>.)</p><p></p><p class="headingAnchor" id="H432641102"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112295.html" rel="external">"Society guideline links: Adrenal insufficiency"</a>.)</p><p class="headingAnchor" id="H17"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classification</strong> – Central adrenal insufficiency results from impaired production of adrenocorticotropic hormone (ACTH). It can be caused by either pituitary disease that impairs release of ACTH (secondary adrenal insufficiency) or by interference with corticotropin-releasing hormone production from the hypothalamus (tertiary adrenal insufficiency). Central adrenal insufficiency may be caused by hypothalamic suppression due to withdrawal from either exogenous or endogenous glucocorticoids (causing transient adrenal insufficiency) or permanent dysfunction or injury to the hypothalamus or pituitary  (<a class="graphic graphic_table graphicRef56675" href="/z/d/graphic/56675.html" rel="external">table 1</a>). (See <a class="local">'Classification'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – The signs and symptoms of central adrenal insufficiency are caused primarily by glucocorticoid deficiency and include weakness, fatigue, myalgia, arthralgia, and hypoglycemia. Hyperpigmentation is absent (in contrast with patients with primary adrenal insufficiency). In addition, some patients may have signs or symptoms related to an underlying central nervous system disease and/or other pituitary hormone deficiencies. (See <a class="local">'Overview of clinical manifestations'</a> above and  <a class="medical medical_review" href="/z/d/html/5828.html" rel="external">"Clinical manifestations and diagnosis of adrenal insufficiency in children", section on 'Central adrenal insufficiency'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Causes of adrenal insufficiency </strong>– For clinical purposes, it is useful to classify central adrenal insufficiency by the expected time course  (<a class="graphic graphic_table graphicRef56675" href="/z/d/graphic/56675.html" rel="external">table 1</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Transient</strong> – Isolated ACTH deficiency resulting from suppression of the hypothalamic-pituitary-adrenal (HPA) axis is the most common cause of adrenal insufficiency. Most cases are the result of abrupt cessation of chronic high-dose exogenous glucocorticoid therapy or other forms of excessive glucocorticoid exposure. The adrenal insufficiency becomes clinically apparent when the glucocorticoid is abruptly withdrawn. (See <a class="local">'Transient central adrenal insufficiency (hypothalamic suppression)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Permanent</strong> – Permanent central adrenal insufficiency can be caused by either pituitary dysfunction (secondary adrenal insufficiency) or hypothalamic dysfunction (tertiary adrenal insufficiency). It can be congenital (eg, brain malformations or syndromes, or genetic defects in pituitary development or function) or acquired (eg, brain injury due to trauma, tumor, radiation, or infiltrative disease). (See <a class="local">'Permanent central adrenal insufficiency'</a> above.)</p><p></p><p class="headingAnchor" id="H742612549"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Patricia A Donohoue, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2016; 101:364.</a></li><li><a class="nounderline abstract_t">Patti G, Guzzeti C, Di Iorgi N, et al. Central adrenal insufficiency in children and adolescents. Best Pract Res Clin Endocrinol Metab 2018; 32:425.</a></li><li><a class="nounderline abstract_t">Rensen N, Gemke RJ, van Dalen EC, et al. Hypothalamic-pituitary-adrenal (HPA) axis suppression after treatment with glucocorticoid therapy for childhood acute lymphoblastic leukaemia. Cochrane Database Syst Rev 2017; 11:CD008727.</a></li><li class="breakAll">Kim MS, Donohoue PA. Adrenal disorders. In: Pediatric Practice: Endocrinology, 2nd ed, Kappy MS, Allen DB, Geffner ME (Eds), McGraw-Hill Medical, New York 2014. p.169.</li><li><a class="nounderline abstract_t">Norman PS, Winkenwerder WL, Agbayani BF, Migeon CJ. Adrenal function during the use of dexamethasone aerosols in the treatment of ragweed hay fever. J Allergy 1967; 40:57.</a></li><li><a class="nounderline abstract_t">Burch PG, Migeon CJ. Systemic absorption of topical steroids. Arch Ophthalmol 1968; 79:174.</a></li><li><a class="nounderline abstract_t">Hollman GA, Allen DB. Overt glucocorticoid excess due to inhaled corticosteroid therapy. Pediatrics 1988; 81:452.</a></li><li><a class="nounderline abstract_t">Russell G. Inhaled corticosteroids and adrenal insufficiency. Arch Dis Child 2002; 87:455.</a></li><li><a class="nounderline abstract_t">Wolfgram PM, Allen DB. Effects of Inhaled Corticosteroids on Growth, Bone Metabolism, and Adrenal Function. Adv Pediatr 2017; 64:331.</a></li><li><a class="nounderline abstract_t">Levin C, Maibach HI. Topical corticosteroid-induced adrenocortical insufficiency: clinical implications. Am J Clin Dermatol 2002; 3:141.</a></li><li><a class="nounderline abstract_t">Nieman LK. Consequences of systemic absorption of topical glucocorticoids. J Am Acad Dermatol 2011; 65:250.</a></li><li><a class="nounderline abstract_t">Ahmet A, Benchimol EI, Goldbloom EB, Barkey JL. Adrenal suppression in children treated with swallowed fluticasone and oral viscous budesonide for eosinophilic esophagitis. Allergy Asthma Clin Immunol 2016; 12:49.</a></li><li><a class="nounderline abstract_t">Charmandari E, Nicolaides NC, Chrousos GP. Adrenal insufficiency. Lancet 2014; 383:2152.</a></li><li><a class="nounderline abstract_t">Michelson D, Galliven E, Hill L, et al. Chronic imipramine is associated with diminished hypothalamic-pituitary-adrenal axis responsivity in healthy humans. J Clin Endocrinol Metab 1997; 82:2601.</a></li><li><a class="nounderline abstract_t">Gold PW, Gwirtsman H, Avgerinos PC, et al. Abnormal hypothalamic-pituitary-adrenal function in anorexia nervosa. Pathophysiologic mechanisms in underweight and weight-corrected patients. N Engl J Med 1986; 314:1335.</a></li><li><a class="nounderline abstract_t">Støving RK. MECHANISMS IN ENDOCRINOLOGY: Anorexia nervosa and endocrinology: a clinical update. Eur J Endocrinol 2019; 180:R9.</a></li><li><a class="nounderline abstract_t">Annane D, Pastores SM, Arlt W, et al. Critical illness-related corticosteroid insufficiency (CIRCI): a narrative review from a Multispecialty Task Force of the Society of Critical Care Medicine (SCCM) and the European Society of Intensive Care Medicine (ESICM). Intensive Care Med 2017; 43:1781.</a></li><li><a class="nounderline abstract_t">Khaper T, Bunge M, Clark I, et al. Increasing incidence of optic nerve hypoplasia/septo-optic dysplasia spectrum: Geographic clustering in Northern Canada. Paediatr Child Health 2017; 22:445.</a></li><li><a class="nounderline abstract_t">McCabe MJ, Alatzoglou KS, Dattani MT. Septo-optic dysplasia and other midline defects: the role of transcription factors: HESX1 and beyond. Best Pract Res Clin Endocrinol Metab 2011; 25:115.</a></li><li><a class="nounderline abstract_t">Bosch I Ara L, Katugampola H, Dattani MT. Congenital Hypopituitarism During the Neonatal Period: Epidemiology, Pathogenesis, Therapeutic Options, and Outcome. Front Pediatr 2020; 8:600962.</a></li><li><a class="nounderline abstract_t">Grugni G, Beccaria L, Corrias A, et al. Central adrenal insufficiency in young adults with Prader-Willi syndrome. Clin Endocrinol (Oxf) 2013; 79:371.</a></li><li><a class="nounderline abstract_t">Corrias A, Grugni G, Crinò A, et al. Assessment of central adrenal insufficiency in children and adolescents with Prader-Willi syndrome. Clin Endocrinol (Oxf) 2012; 76:843.</a></li><li><a class="nounderline abstract_t">Muscogiuri G, Formoso G, Pugliese G, et al. Prader- Willi syndrome: An uptodate on endocrine and metabolic complications. Rev Endocr Metab Disord 2019; 20:239.</a></li><li><a class="nounderline abstract_t">de Lind van Wijngaarden RF, Otten BJ, Festen DA, et al. High prevalence of central adrenal insufficiency in patients with Prader-Willi syndrome. J Clin Endocrinol Metab 2008; 93:1649.</a></li><li><a class="nounderline abstract_t">Ize-Ludlow D, Gray JA, Sperling MA, et al. Rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation presenting in childhood. Pediatrics 2007; 120:e179.</a></li><li><a class="nounderline abstract_t">de Moraes DC, Vaisman M, Conceição FL, Ortiga-Carvalho TM. Pituitary development: a complex, temporal regulated process dependent on specific transcriptional factors. J Endocrinol 2012; 215:239.</a></li><li><a class="nounderline abstract_t">Vallette-Kasic S, Barlier A, Teinturier C, et al. PROP1 gene screening in patients with multiple pituitary hormone deficiency reveals two sites of hypermutability and a high incidence of corticotroph deficiency. J Clin Endocrinol Metab 2001; 86:4529.</a></li><li><a class="nounderline abstract_t">Shi C, Wang F, Tong A, et al. NFKB2 mutation in common variable immunodeficiency and isolated adrenocorticotropic hormone deficiency: A case report and review of literature. Medicine (Baltimore) 2016; 95:e5081.</a></li><li><a class="nounderline abstract_t">Lal RA, Bachrach LK, Hoffman AR, et al. A Case Report of Hypoglycemia and Hypogammaglobulinemia: DAVID Syndrome in a Patient With a Novel NFKB2 Mutation. J Clin Endocrinol Metab 2017; 102:2127.</a></li><li><a class="nounderline abstract_t">Jackson RS, Creemers JW, Farooqi IS, et al. Small-intestinal dysfunction accompanies the complex endocrinopathy of human proprotein convertase 1 deficiency. J Clin Invest 2003; 112:1550.</a></li><li><a class="nounderline abstract_t">Farooqi IS, Volders K, Stanhope R, et al. Hyperphagia and early-onset obesity due to a novel homozygous missense mutation in prohormone convertase 1/3. J Clin Endocrinol Metab 2007; 92:3369.</a></li><li><a class="nounderline abstract_t">Pépin L, Colin E, Tessarech M, et al. A New Case of PCSK1 Pathogenic Variant With Congenital Proprotein Convertase 1/3 Deficiency and Literature Review. J Clin Endocrinol Metab 2019; 104:985.</a></li><li><a class="nounderline abstract_t">Martín MG, Lindberg I, Solorzano-Vargas RS, et al. Congenital proprotein convertase 1/3 deficiency causes malabsorptive diarrhea and other endocrinopathies in a pediatric cohort. Gastroenterology 2013; 145:138.</a></li><li><a class="nounderline abstract_t">Xatzipsalti M, Voutetakis A, Stamoyannou L, et al. Congenital Hypopituitarism: Various Genes, Various Phenotypes. Horm Metab Res 2019; 51:81.</a></li><li><a class="nounderline abstract_t">Constine LS, Woolf PD, Cann D, et al. Hypothalamic-pituitary dysfunction after radiation for brain tumors. N Engl J Med 1993; 328:87.</a></li><li><a class="nounderline abstract_t">Kanumakala S, Warne GL, Zacharin MR. Evolving hypopituitarism following cranial irradiation. J Paediatr Child Health 2003; 39:232.</a></li><li><a class="nounderline abstract_t">Sklar CA, Antal Z, Chemaitilly W, et al. Hypothalamic-Pituitary and Growth Disorders in Survivors of Childhood Cancer: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2018; 103:2761.</a></li><li><a class="nounderline abstract_t">Huang KE, Mittelman SD, Coates TD, et al. A significant proportion of thalassemia major patients have adrenal insufficiency detectable on provocative testing. J Pediatr Hematol Oncol 2015; 37:54.</a></li><li><a class="nounderline abstract_t">De Sanctis V, Elsedfy H, Soliman AT, et al. The Diagnostic Approach to Central Adrenocortical Insufficiency (CAI) in Thalassemia. Mediterr J Hematol Infect Dis 2016; 8:e2016026.</a></li><li><a class="nounderline abstract_t">Elsedfy HH, El Kholy M, Hamza RT, et al. Adrenal function in thalassemia major adolescents. Pediatr Endocrinol Rev 2011; 8 Suppl 2:295.</a></li><li><a class="nounderline abstract_t">Noetzli LJ, Panigrahy A, Mittelman SD, et al. Pituitary iron and volume predict hypogonadism in transfusional iron overload. Am J Hematol 2012; 87:167.</a></li></ol></div><div id="topicVersionRevision">Topic 5815 Version 24.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26760044" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30086867" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Central adrenal insufficiency in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29106702" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Hypothalamic-pituitary-adrenal (HPA) axis suppression after treatment with glucocorticoid therapy for childhood acute lymphoblastic leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29106702" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Hypothalamic-pituitary-adrenal (HPA) axis suppression after treatment with glucocorticoid therapy for childhood acute lymphoblastic leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5230040" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Adrenal function during the use of dexamethasone aerosols in the treatment of ragweed hay fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5635343" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Systemic absorption of topical steroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3344190" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Overt glucocorticoid excess due to inhaled corticosteroid therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12456537" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Inhaled corticosteroids and adrenal insufficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28688596" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Effects of Inhaled Corticosteroids on Growth, Bone Metabolism, and Adrenal Function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11978135" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Topical corticosteroid-induced adrenocortical insufficiency: clinical implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21679844" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Consequences of systemic absorption of topical glucocorticoids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27766109" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Adrenal suppression in children treated with swallowed fluticasone and oral viscous budesonide for eosinophilic esophagitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24503135" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Adrenal insufficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9253341" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Chronic imipramine is associated with diminished hypothalamic-pituitary-adrenal axis responsivity in healthy humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3010109" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Abnormal hypothalamic-pituitary-adrenal function in anorexia nervosa. Pathophysiologic mechanisms in underweight and weight-corrected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30400050" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : MECHANISMS IN ENDOCRINOLOGY: Anorexia nervosa and endocrinology: a clinical update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28940017" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Critical illness-related corticosteroid insufficiency (CIRCI): a narrative review from a Multispecialty Task Force of the Society of Critical Care Medicine (SCCM) and the European Society of Intensive Care Medicine (ESICM).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29479262" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Increasing incidence of optic nerve hypoplasia/septo-optic dysplasia spectrum: Geographic clustering in Northern Canada.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21396578" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Septo-optic dysplasia and other midline defects: the role of transcription factors: HESX1 and beyond.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33634051" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Congenital Hypopituitarism During the Neonatal Period: Epidemiology, Pathogenesis, Therapeutic Options, and Outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23311724" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Central adrenal insufficiency in young adults with Prader-Willi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22150958" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Assessment of central adrenal insufficiency in children and adolescents with Prader-Willi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31065942" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Prader- Willi syndrome: An uptodate on endocrine and metabolic complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18303077" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : High prevalence of central adrenal insufficiency in patients with Prader-Willi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17606542" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation presenting in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22872762" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Pituitary development: a complex, temporal regulated process dependent on specific transcriptional factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11549703" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : PROP1 gene screening in patients with multiple pituitary hormone deficiency reveals two sites of hypermutability and a high incidence of corticotroph deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27749582" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : NFKB2 mutation in common variable immunodeficiency and isolated adrenocorticotropic hormone deficiency: A case report and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28472507" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : A Case Report of Hypoglycemia and Hypogammaglobulinemia: DAVID Syndrome in a Patient With a Novel NFKB2 Mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14617756" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Small-intestinal dysfunction accompanies the complex endocrinopathy of human proprotein convertase 1 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17595246" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Hyperphagia and early-onset obesity due to a novel homozygous missense mutation in prohormone convertase 1/3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30383237" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : A New Case of PCSK1 Pathogenic Variant With Congenital Proprotein Convertase 1/3 Deficiency and Literature Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23562752" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Congenital proprotein convertase 1/3 deficiency causes malabsorptive diarrhea and other endocrinopathies in a pediatric cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30759489" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Congenital Hypopituitarism: Various Genes, Various Phenotypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8416438" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Hypothalamic-pituitary dysfunction after radiation for brain tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12654151" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Evolving hypopituitarism following cranial irradiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29982476" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Hypothalamic-Pituitary and Growth Disorders in Survivors of Childhood Cancer: An Endocrine Society Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24942024" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : A significant proportion of thalassemia major patients have adrenal insufficiency detectable on provocative testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27158439" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The Diagnostic Approach to Central Adrenocortical Insufficiency (CAI) in Thalassemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21705981" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Adrenal function in thalassemia major adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22213195" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Pituitary iron and volume predict hypogonadism in transfusional iron overload.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
